HARMONY BIOSCIENCES HLDGS IN's ticker is HRMY and the CUSIP is 413197104. A total of 241 filers reported holding HARMONY BIOSCIENCES HLDGS IN in Q4 2022. The put-call ratio across all filers is 1.21 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,648,948 | +4.1% | 996,306 | +11.8% | 1.09% | +19.9% |
| Q2 2023 | $31,367,310 | +860.7% | 891,370 | +791.4% | 0.91% | +845.8% |
| Q1 2023 | $3,265,000 | -85.6% | 100,000 | -75.7% | 0.10% | -84.9% |
| Q4 2022 | $22,690,400 | +24.4% | 411,804 | 0.0% | 0.64% | +20.4% |
| Q3 2022 | $18,239,000 | -9.2% | 411,804 | 0.0% | 0.53% | -15.9% |
| Q2 2022 | $20,084,000 | -1.6% | 411,804 | -13.9% | 0.63% | +300.6% |
| Q4 2021 | $20,404,000 | +8.3% | 478,516 | -2.6% | 0.16% | -42.7% |
| Q3 2021 | $18,833,000 | -32.1% | 491,332 | -50.0% | 0.27% | +52.2% |
| Q2 2021 | $27,740,000 | +169.4% | 982,664 | +215.3% | 0.18% | +38.5% |
| Q1 2021 | $10,298,000 | -43.3% | 311,673 | -38.0% | 0.13% | -33.3% |
| Q4 2020 | $18,170,000 | +23.1% | 502,622 | +15.4% | 0.20% | -9.3% |
| Q3 2020 | $14,759,000 | – | 435,377 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Valor Management LLC | 11,218,033 | $618,113,619 | 97.50% |
| venBio Partners LLC | 1,035,396 | $57,050,320 | 17.69% |
| Vivo Capital, LLC | 2,606,247 | $143,604 | 16.53% |
| Nan Fung Group Holdings Ltd | 368,665 | $20,313,442 | 14.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 264,500 | $14,560,725 | 4.50% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 685,340 | $37,762,234 | 3.51% |
| ASHFORD CAPITAL MANAGEMENT INC | 356,638 | $19,650,754 | 3.05% |
| TANG CAPITAL MANAGEMENT LLC | 281,200 | $15,494,120 | 2.25% |
| MPM BioImpact LLC | 139,377 | $7,679,673 | 1.99% |
| O'Neil Global Advisors, Inc. | 7,335 | $404 | 1.86% |